🇺🇸 FDA
Pipeline program

-, Apalutamide placebo, JNJ-56021927

56021927PCR3002

Phase 3 small_molecule active

Quick answer

-, Apalutamide placebo, JNJ-56021927 for Metastatic Hormone-sensitive Prostate Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Metastatic Hormone-sensitive Prostate Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials